180 Life Sciences Corp (NASDAQ:ATNF) — Stock Price
180 Life Sciences Corp (NASDAQ:ATNF) is currently trading at $16.80 USD, up 905.99% today. Over the past 52 weeks, shares have ranged between $1.67 and $16.80. This page tracks 180 Life Sciences Corp's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 180 Life Sciences Corp market cap and net worth.
180 Life Sciences Corp (ATNF) Stock Price Chart — Daily History & Trading Volume
The chart below tracks 180 Life Sciences Corp's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
180 Life Sciences Corp Income Statement — Revenue, Profit & Earnings by Year
180 Life Sciences Corp's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $58.28K | $105.67K | $109.00K | $116.30K | — |
| Gross Profit | $-58.28K | $-105.67K | $-109.00K | $-116.30K | — |
| Research & Development | $1.97 Million | $2.78 Million | $2.43 Million | $3.95 Million | $2.29 Million |
| SG&A | $4.36 Million | $10.69 Million | $15.47 Million | $3.36 Million | $3.36 Million |
| Total Operating Expenses | $6.27 Million | $13.37 Million | $17.90 Million | $5.65 Million | $5.65 Million |
| Operating Income | $-6.32 Million | $-13.48 Million | $-17.90 Million | $-5.65 Million | $-5.65 Million |
| EBITDA | $-6.32 Million | $-22.13 Million | $-17.79 Million | $-9.69 Million | $-5.26 Million |
| EBIT | $-6.51 Million | $-22.24 Million | $-17.90 Million | $-9.82 Million | $-5.38 Million |
| Interest Expense | $50.64K | $44.83 | $26.67K | $1.09 Million | $1.09 Million |
| Income Before Tax | $-6.46 Million | $-22.28 Million | $-39.67 Million | $-10.90 Million | $-10.90 Million |
| Income Tax Expense | $-296.02K | $-2.35 Million | $-942.75K | $-20.43K | $-20.43K |
| Net Income | $-6.17 Million | $-19.94 Million | $-38.73 Million | $-10.88 Million | $-10.88 Million |
180 Life Sciences Corp Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes 180 Life Sciences Corp's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $12.76 Million | $5.26 Million | $19.65 Million | $62.71 Million | $55.53 Million |
| Total Current Assets | $5.14 Million | $3.64 Million | $8.93 Million | $11.20 Million | $4.01 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $41.19K | $279.04K | $310.02K | $80.78K | $784.64K |
| Inventory | — | — | $-620.97K | $2.23 Million | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | $0.00 | $36.99 Million | $36.90 Million |
| Total Liabilities | $3.51 Million | $5.39 Million | $8.31 Million | $23.39 Million | $25.25 Million |
| Total Current Liabilities | $3.50 Million | $5.06 Million | $5.66 Million | $19.70 Million | $21.42 Million |
| Long-term Debt | $6.62K | $19.94K | $31.19K | $48.16K | $113.76K |
| Net Debt | $-4.43 Million | $-655.73K | $-5.63 Million | $-6.27 Million | $1.67 Million |
| Total Stockholder Equity | $9.25 Million | $-127.73K | $11.34 Million | $39.32 Million | $30.29 Million |
| Retained Earnings | $-141.52 Million | $-127.34 Million | $-107.41 Million | $-68.68 Million | $-48.36 Million |
180 Life Sciences Corp Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how 180 Life Sciences Corp generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-1.48 Million | $-10.92 Million | $-12.13 Million | $-3.87 Million | $-3.87 Million |
| Capital Expenditures | $0.00 | $3.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-1.48 Million | $-10.92 Million | $-12.13 Million | $-3.87 Million | $-3.87 Million |
| Investing Cash Flow | — | — | — | $14.49 Million | $14.49 Million |
| Financing Cash Flow | $4.04 Million | $5.91 Million | $10.87 Million | $-8.73 Million | $-8.73 Million |
| Dividends Paid | $8.01 Million | — | — | $474.77K | — |
| Stock-Based Compensation | $308.17K | $2.28 Million | $2.97 Million | $1.12 Million | $1.12 Million |
| Depreciation | $58.28K | $105.67K | $109.00K | $125.33K | $125.33K |
| Change in Cash | $2.61 Million | $-4.99 Million | $-1.25 Million | $2.03 Million | $-8.73 Million |
180 Life Sciences Corp Earnings History — EPS Actual vs. Analyst Estimates
Track 180 Life Sciences Corp's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 14, 2025 | -16.80 | 0.00 | — |
| Jul 23, 2025 | -3.02 | — | — |
| May 13, 2025 | -0.67 | — | — |
| Mar 20, 2025 | -3.87 | — | — |
| Nov 07, 2024 | -0.85 | — | — |
| Aug 12, 2024 | 0.01 | — | — |
| May 15, 2024 | -1.68 | — | — |
| Mar 25, 2024 | -26.60 | 3.80 | -800.00% |